- A2 Bio Highlights Progress of TmodTM CAR T-Cell Clinical Programs
- Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy
- Alligator Bioscience Presents an Update with Clinical and Biomarker Results with Mitazalimab in Phase 2 Pancreatic Cancer
- Allogene Therapeutics Announces Positive Ph 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma
- Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Ph 1 Study of Breast Cancer Vaccine
- Aummune Announces Results from Phase 1 Trial of its Novel AM003 Immunotherapy for the Treatment of Solid Tumors
- BeyondSpring Presents Updated Efficacy Results from Ph 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors
- Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in mCRPC
- Cue Biopharma Presents Positive Updated Data from Ph 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers
- Domvanalimab + Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High NSCLC
- Elicio Therapeutics Presents Updated Translational Data from ELI-002 Ph 1 AMPLIFY-7P Study
- Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors
- GenVivo Presents Ph 1 Trial Results for GEN2
- Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20
- ImCheck Presents Updated Data from the EVICTION Trial
- Immatics N.V. announced expanded clinical dataset from the ongoing Ph 1b dose expansion clinical trial for ACTengine® IMA203 in addition to updated Ph 1 dose escalation clinical data on ACTengine® IMA203CD8 TCR-T cell therapy
- IMUNON Presents Positive Data from Ph 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer
- IO102-IO103 + KEYTRUDA Demonstrates Promising Activity and Durability in 1L Treatment of Patients with Metastatic Lung Cancer in Ph 2 IOB-022 Study
- Kineta Updates KVA12123 Clinical Results from Ongoing Ph 1/2 VISTA101 Study
- Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA
- MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers
- Mural Oncology Presents Clinical Data Across its Pipeline
- Positive Ph 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma Announced
- Replimune Presents Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma
- Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer
- Xilio Therapeutics Announces Initial Clinical Trial Data from Ph 1C Dose Escalation for Vilastobart (XTX101) in Combination with Atezolizumab in Patients with Advanced Solid Tumors
